Vestal Point Capital’s Vaxcyte PCVX Stock Holding History

Vestal Point Capital’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-525,000	Closed	-$33M	–	69
2023 Q4	$33M	Buy	+525,000	New	+$27.3M	3.49%	10

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vestal Point Capital's PCVX Position: Q1 2024 in Review

Vestal Point Capital sold out of Vaxcyte (PCVX) in Q1 2024, closing a stake of 525,000 shares — an estimated $33M sold.

Vestal Point Capital first reported a position in PCVX in Q4 2023 and held it in 1 quarter. The position peaked at $33M in Q4 2023. 251 funds tracked by Wall St. Rank hold PCVX as of Q1 2024.

Vestal Point Capital reported no remaining Vaxcyte position as of Q1 2024 after selling out during the quarter.
Vestal Point Capital sold 525,000 Vaxcyte shares in Q1 2024, an estimated $33M.
Vestal Point Capital first reported a position in Vaxcyte in Q4 2023 and held it in 1 quarter.
Vestal Point Capital's Vaxcyte position peaked at $33M in Q4 2023.
251 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2024.

Based on Vestal Point Capital's 13F filing for Q1 2024, filed 14 May 2024.